Tags

Type your tag names separated by a space and hit enter

Adolescent meningococcal serogroup A, W and Y immune responses following immunization with quadrivalent meningococcal A, C, W and Y conjugate vaccine: Optimal age for vaccination.
Vaccine. 2017 08 24; 35(36):4753-4760.V

Abstract

BACKGROUND

Recently the incidence of meningococcal serogroup Y (MenY) and in particular serogroup W (MenW) invasive disease has risen in several European countries, including the Netherlands. Adolescents are a target group for primary prevention through vaccination to protect against disease and reduce carriage and induce herd protection in the population. The present study assessed MenA, MenW and MenY antibody levels in adolescents up to one year following primary vaccination with quadrivalent MenACWY-PS conjugated to tetanus toxoid (MenACWY-TT).

METHODS

In this phase IV, open-label study, healthy 10-, 12- and 15-year-olds received the MenACWY-TT vaccine. Blood samples were collected before, 1month and 1year after the vaccination. Functional antibody levels against MenA, MenW and MenY were measured with serum bactericidal assay using baby rabbit complement (rSBA). MenA-, MenW-, and MenY-PS specific IgG, IgG1 and IgG2 levels were measured using fluorescent-bead-based multiplex immunoassay.

RESULTS

The quadrivalent MenACWY-TT vaccine elicited robust antibody responses against MenA, MenW and MenY, and the majority (94%) of the participants maintained rSBA titers ≥128 one year after the vaccination against all three serogroups. After one year, higher MenW rSBA GMTs were observed in the 12- and 15-year-olds compared to the 10-year-olds, while rSBA GMTs against MenA and MenY were similar between age groups. Furthermore, those participant who showed SBA titer ≥8 at baseline, also had higher antibody levels one year after vaccination as compared to participants with rSBA titer <8 at baseline.

CONCLUSION

The MenACWY-TT vaccine induces robust protective primary immune responses up to one year after vaccination. Our results suggest that persistence of individual protection increases with the age at which a primary quadrivalent MenACWY-TT vaccination is administered. Our results indicate that 12 or 15years seems a more optimal age for a primary quadrivalent MenACWY-TT vaccination to protect against the rapid increase of MenW disease.

Authors+Show Affiliations

Centre for Infectious Disease Control (Cib), National Institute of Public Health and the Environment (RIVM), Bilthoven, The Netherlands; Department of Pediatric Immunology and Infectious Diseases, Wilhelmina Children's Hospital, University Medical Center, Utrecht, The Netherlands. Electronic address: mariette.van.ravenhorst@rivm.nl.Centre for Infectious Disease Control (Cib), National Institute of Public Health and the Environment (RIVM), Bilthoven, The Netherlands.Centre for Infectious Disease Control (Cib), National Institute of Public Health and the Environment (RIVM), Bilthoven, The Netherlands.Centre for Infectious Disease Control (Cib), National Institute of Public Health and the Environment (RIVM), Bilthoven, The Netherlands; Department of Pediatric Immunology and Infectious Diseases, Wilhelmina Children's Hospital, University Medical Center, Utrecht, The Netherlands.Centre for Infectious Disease Control (Cib), National Institute of Public Health and the Environment (RIVM), Bilthoven, The Netherlands. Electronic address: guy.berbers@rivm.nl.

Pub Type(s)

Clinical Trial, Phase IV
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

28647167

Citation

van Ravenhorst, Mariëtte B., et al. "Adolescent Meningococcal Serogroup A, W and Y Immune Responses Following Immunization With Quadrivalent Meningococcal A, C, W and Y Conjugate Vaccine: Optimal Age for Vaccination." Vaccine, vol. 35, no. 36, 2017, pp. 4753-4760.
van Ravenhorst MB, van der Klis FRM, van Rooijen DM, et al. Adolescent meningococcal serogroup A, W and Y immune responses following immunization with quadrivalent meningococcal A, C, W and Y conjugate vaccine: Optimal age for vaccination. Vaccine. 2017;35(36):4753-4760.
van Ravenhorst, M. B., van der Klis, F. R. M., van Rooijen, D. M., Sanders, E. A. M., & Berbers, G. A. M. (2017). Adolescent meningococcal serogroup A, W and Y immune responses following immunization with quadrivalent meningococcal A, C, W and Y conjugate vaccine: Optimal age for vaccination. Vaccine, 35(36), 4753-4760. https://doi.org/10.1016/j.vaccine.2017.06.007
van Ravenhorst MB, et al. Adolescent Meningococcal Serogroup A, W and Y Immune Responses Following Immunization With Quadrivalent Meningococcal A, C, W and Y Conjugate Vaccine: Optimal Age for Vaccination. Vaccine. 2017 08 24;35(36):4753-4760. PubMed PMID: 28647167.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Adolescent meningococcal serogroup A, W and Y immune responses following immunization with quadrivalent meningococcal A, C, W and Y conjugate vaccine: Optimal age for vaccination. AU - van Ravenhorst,Mariëtte B, AU - van der Klis,Fiona R M, AU - van Rooijen,Debbie M, AU - Sanders,Elisabeth A M, AU - Berbers,Guy A M, Y1 - 2017/06/21/ PY - 2017/02/24/received PY - 2017/06/01/revised PY - 2017/06/02/accepted PY - 2017/6/26/pubmed PY - 2018/4/20/medline PY - 2017/6/26/entrez KW - Adolescent KW - Antibody KW - Conjugate vaccine KW - Neisseria meningitidis KW - Quadrivalent meningococcal vaccine SP - 4753 EP - 4760 JF - Vaccine JO - Vaccine VL - 35 IS - 36 N2 - BACKGROUND: Recently the incidence of meningococcal serogroup Y (MenY) and in particular serogroup W (MenW) invasive disease has risen in several European countries, including the Netherlands. Adolescents are a target group for primary prevention through vaccination to protect against disease and reduce carriage and induce herd protection in the population. The present study assessed MenA, MenW and MenY antibody levels in adolescents up to one year following primary vaccination with quadrivalent MenACWY-PS conjugated to tetanus toxoid (MenACWY-TT). METHODS: In this phase IV, open-label study, healthy 10-, 12- and 15-year-olds received the MenACWY-TT vaccine. Blood samples were collected before, 1month and 1year after the vaccination. Functional antibody levels against MenA, MenW and MenY were measured with serum bactericidal assay using baby rabbit complement (rSBA). MenA-, MenW-, and MenY-PS specific IgG, IgG1 and IgG2 levels were measured using fluorescent-bead-based multiplex immunoassay. RESULTS: The quadrivalent MenACWY-TT vaccine elicited robust antibody responses against MenA, MenW and MenY, and the majority (94%) of the participants maintained rSBA titers ≥128 one year after the vaccination against all three serogroups. After one year, higher MenW rSBA GMTs were observed in the 12- and 15-year-olds compared to the 10-year-olds, while rSBA GMTs against MenA and MenY were similar between age groups. Furthermore, those participant who showed SBA titer ≥8 at baseline, also had higher antibody levels one year after vaccination as compared to participants with rSBA titer <8 at baseline. CONCLUSION: The MenACWY-TT vaccine induces robust protective primary immune responses up to one year after vaccination. Our results suggest that persistence of individual protection increases with the age at which a primary quadrivalent MenACWY-TT vaccination is administered. Our results indicate that 12 or 15years seems a more optimal age for a primary quadrivalent MenACWY-TT vaccination to protect against the rapid increase of MenW disease. SN - 1873-2518 UR - https://www.unboundmedicine.com/medline/citation/28647167/Adolescent_meningococcal_serogroup_A_W_and_Y_immune_responses_following_immunization_with_quadrivalent_meningococcal_A_C_W_and_Y_conjugate_vaccine:_Optimal_age_for_vaccination_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0264-410X(17)30784-3 DB - PRIME DP - Unbound Medicine ER -